Shares of Becton Dickinson and Co (NYSE:BDX) have earned an average rating of “Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $257.45.
BDX has been the topic of a number of recent analyst reports. ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, April 1st. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Barclays boosted their price objective on Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a research note on Monday, April 15th. Raymond James decreased their price objective on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, March 19th. Finally, TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th.
Shares of BDX stock opened at $232.55 on Friday. The company has a market capitalization of $64.01 billion, a price-to-earnings ratio of 21.12, a price-to-earnings-growth ratio of 1.68 and a beta of 1.16. The company has a quick ratio of 0.62, a current ratio of 0.97 and a debt-to-equity ratio of 0.83. Becton Dickinson and has a fifty-two week low of $208.62 and a fifty-two week high of $265.87.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 7th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 1.32%. The ex-dividend date of this dividend is Thursday, June 6th. Becton Dickinson and’s payout ratio is 27.97%.
In related news, CEO Vincent A. Forlenza sold 11,340 shares of the business’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the completion of the transaction, the chief executive officer now directly owns 227,250 shares in the company, valued at $56,903,400. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Vincent A. Forlenza sold 8,309 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $255.13, for a total value of $2,119,875.17. Following the transaction, the chief executive officer now owns 222,785 shares of the company’s stock, valued at $56,839,137.05. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,684 shares of company stock valued at $7,518,574. 0.12% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of BDX. Harvest Group Wealth Management LLC purchased a new position in shares of Becton Dickinson and in the 1st quarter worth about $25,000. Pinnacle Financial Partners Inc. purchased a new position in shares of Becton Dickinson and in the 1st quarter worth about $29,000. RPG Investment Advisory LLC purchased a new position in shares of Becton Dickinson and in the 1st quarter worth about $32,000. Nalls Sherbakoff Group LLC purchased a new position in shares of Becton Dickinson and in the 4th quarter worth about $34,000. Finally, Aspire Private Capital LLC purchased a new stake in Becton Dickinson and during the 4th quarter valued at about $39,000. Institutional investors and hedge funds own 84.96% of the company’s stock.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: The role of implied volatility with call option volume
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.